Eureka Therapeutics has published a proof-of-concept study
in OncoImmunology entitled “Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.”
Inspired by the results of checkpoint therapies such as PD-1, which reduce immune system suppressing aspects of cancerous tumors, Eureka developed a therapy that aims to deplete the the regulatory t-cells within tumors as means of weakening their defenses to other therapies used to combat cancer.
Eureka’s therapy uses an antibody that targets the foxp3 protein within tumors as a means of shutting off it’s defenses. There are several other experimental procedures that aim to do this in other ways, however, Eureka’s method appears to target the defenses better.
The therapy is still in the preclinical stages, but the overall approach seems to show promise as another weapon in the arsenal against cancer
You can read Eureka Therapeutics’ press release here: https://www.eurekatherapeutics.com/media/press-releases/041519/